Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors

In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regardin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Comput Struct Biotechnol J
Main Authors: Heydt, Carina, Becher, Ann-Kathrin, Wagener-Ryczek, Svenja, Ball, Markus, Schultheis, Anne M., Schallenberg, Simon, Rüsseler, Vanessa, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Formato: Artigo
Idioma:Inglês
Publicado em: Research Network of Computational and Structural Biotechnology 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861603/
https://ncbi.nlm.nih.gov/pubmed/31762957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.csbj.2019.09.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados